{"organizations": [], "uuid": "662e1b86c622edd1eceed7fb8d641d92ca9cce99", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180327.html", "section_title": "Archive News &amp; Video for Tuesday, 27 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-merck-receives-fast-track-designat/brief-merck-receives-fast-track-designation-for-tepotinib-in-non-small-cell-lung-cancer-in-japan-idUSFWN1R90KJ", "country": "US", "domain_rank": 408, "title": "BRIEF-Merck Receives Fast-Track Designation For Tepotinib In Non-Small Cell Lung Cancer In Japan", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-03-27T20:43:00.000+03:00", "replies_count": 0, "uuid": "662e1b86c622edd1eceed7fb8d641d92ca9cce99"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-merck-receives-fast-track-designat/brief-merck-receives-fast-track-designation-for-tepotinib-in-non-small-cell-lung-cancer-in-japan-idUSFWN1R90KJ", "ord_in_thread": 0, "title": "BRIEF-Merck Receives Fast-Track Designation For Tepotinib In Non-Small Cell Lung Cancer In Japan", "locations": [], "entities": {"persons": [], "locations": [{"name": "japan", "sentiment": "none"}], "organizations": [{"name": "tepotinib", "sentiment": "negative"}, {"name": "reuters) - merck & co inc", "sentiment": "neutral"}, {"name": "merck & co inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 27 (Reuters) - Merck & Co Inc:\n* MERCK RECEIVES FAST-TRACK DESIGNATION FOR TEPOTINIB IN NON-SMALL CELL LUNG CANCER IN JAPAN\n* MERCK & CO INC - ‍SAKIGAKE DESIGNATION ENCOMPASSES POSSIBILITY FOR A TARGET REVIEW PERIOD OF 6 MONTHS​\n* MERCK & CO INC - ‍JAPANESE MINISTRY OF HEALTH, LABOUR AND WELFARE GRANTS SAKIGAKE DESIGNATION FOR TEPOTINIB​ Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-03-27T20:43:00.000+03:00", "crawled": "2018-03-28T19:21:50.044+03:00", "highlightTitle": ""}